Table 1 Role for Fc-dependent BnAb functions for protection from cell free virus in vivo
From: Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies
Aim of study | BnAb studied | Model | Outcome | References |
|---|---|---|---|---|
Compare wild type b12 with b12 versions deficient for FcR binding and/or complement binding for protection of macaques from high-dose SHIV challenge | b12 | Macaque high-dose SHIV | Elimination of the ability of b12 to engage FcR diminished the ability of the antibody to protect macaques from high-dose SHIV challenge | [5] |
Compare low doses of wild type b12 and b12 deficient for FcR binding for protection of macaques from repeated low-dose SHIV challenge | b12 | Macaque repeated low-dose SHIV | More challenges did not result in infection of animals infused with wild type b12, as compared to animals infused with b12 deficient in FcR binding | [35] |
Assess if low doses of a non-fucosylated version of b12, with enhanced ADCC potential, are better than wild type b12 for protecting macaques from repeated low-dose SHIV challenge | b12 | Macaque repeated low-dose SHIV | Non-fucosylated b12 did not provide enhanced protection from repeated low-dose SHIV challenge, as compared to wild type b12 | [36] |
Screen panel of BnAbs with enhanced of diminished FcR binding for ability to block viral entry in a murine model | BnAb panel | Murine HIV-1 entry | BnAbs with enhanced FcR binding demonstrated enhanced in vivo blocking of HIV-1 entry | [20] |
Determine if modifying VRC01 to enhance binding to FcRn improves the ability of suboptimal doses of the BnAb to protect against SHIV challenge | VRC01 | Macaque SHIV | Suboptimal doses of VRC01 with enhanced binding to FcRn protected more macaques from SHIV challenge than wild type VRC01 | [31] |